Bristol Myers Squibb (NYSE: BMY) announced a strategic agreement with Anthropic to deploy Claude artificial intelligence technology across its global operations, according to a company statement. The pharmaceutical company will provide Claude access to more than 30,000 employees across research, clinical development, manufacturing, commercial, and corporate functions.

The deployment focuses on three areas: accelerating software development through Claude Code for engineering teams, embedding AI agents into drug development workflows, and connecting Claude to institutional knowledge across company systems.

BMS plans to use Claude in research to analyze proprietary scientific and clinical data for target identification across oncology, hematology, neuroscience, and immunology. In drug development, the AI will support clinical study documentation and regulatory submissions. Manufacturing applications include root-cause investigations and batch release decisions, while commercial uses involve field insights and healthcare professional engagement.

"Anthropic's Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee," said Greg Meyers, executive vice president and chief digital and technology officer at Bristol Myers Squibb.

The collaboration builds on BMS's three-year AI investment program that has provided employees access to frontier AI models through an internal platform. The company follows a multi-vendor AI strategy across its operations.

Eric Kauderer-Abrams, head of life sciences at Anthropic, stated that the partnership creates "a single intelligence layer" connected to thousands of data sources across BMS to accelerate medicine development processes.